Atara biotherapeutics to present new open-label extension data, including 15-month safety and efficacy data from highest dose cohorts, in the phase1a study of ata188 for progressive forms of multiple sclerosis at the ecf 28th annual meeting

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the company will present for the first time 15-month safety and efficacy data from all patients in the two highest dose cohorts of the phase 1a open-label extension (o
ATRA Ratings Summary
ATRA Quant Ranking